Last reviewed · How we verify
Pegulicianine
Pegulicianine is a Small molecule drug developed by Massachusetts General Hospital. It is currently FDA-approved. Also known as: LUMISIGHT.
At a glance
| Generic name | Pegulicianine |
|---|---|
| Also known as | LUMISIGHT |
| Sponsor | Massachusetts General Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Boxed warnings
- WARNING: ANAPHYLAXIS AND OTHER SERIOUS HYPERSENSITIVITY REACTIONS Serious hypersensitivity reactions, including anaphylaxis, can occur during or following administration of LUMISIGHT. Anaphylaxis occurred in 4/726 (0.6%) of patients in clinical studies. Signs and symptoms associated with other hypersensitivity reactions included pruritus, urticaria, hypotension, lip swelling, erythema, anxiety, chest pain, cyanosis, dizziness, dyspnea, headache, hypoesthesia, hyperventilation, maculopapular rash
Common side effects
- Chromaturia
- Hypersensitivity
Serious adverse events
- Anaphylaxis
- Skin discoloration after extravasation
- Dyspnea
- Pyrexia
- Vomiting
- Nausea
Key clinical trials
- The Impact of Surgeon-Interpreted Intraoperative Margin Assessment During Breast Conserving Surgery on Postoperative Treatment
- Study to Image Inflammatory Activity of a Fluorescence Imaging Agent in Excised Human Artery Plaques (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pegulicianine CI brief — competitive landscape report
- Pegulicianine updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI
Frequently asked questions about Pegulicianine
What is Pegulicianine?
Pegulicianine is a Small molecule drug developed by Massachusetts General Hospital.
Who makes Pegulicianine?
Pegulicianine is developed and marketed by Massachusetts General Hospital (see full Massachusetts General Hospital pipeline at /company/massachusetts-general-hospital).
Is Pegulicianine also known as anything else?
Pegulicianine is also known as LUMISIGHT.
What development phase is Pegulicianine in?
Pegulicianine is FDA-approved (marketed).
What are the side effects of Pegulicianine?
Common side effects of Pegulicianine include Chromaturia, Hypersensitivity. Serious adverse events: Anaphylaxis, Skin discoloration after extravasation, Dyspnea, Pyrexia.
Related
- Manufacturer: Massachusetts General Hospital — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: LUMISIGHT
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing